程序性死亡配体1表达与黑色素瘤对抗程序性死亡1抗体帕博利珠单抗的应答
本研究基于Ib期KEYNOTE-001研究,分析655例接受帕博利珠单抗治疗的晚期黑色素瘤患者中PD-L1表达与疗效的关系。在451例可评估PD-L1表达的患者中,344例(76%)为PD-L1阳性。PD-L1表达(MEL评分)越高,客观缓解率、无进展生存期和总生存期越好,但PD-L1阴性肿瘤患者也可能获得持久缓解。
要点
- 帕博利珠单抗10 mg/kg每2周或每3周,或2 mg/kg每3周给药。
- MEL评分≥2(≥1%细胞膜染色)定义为PD-L1阳性。
- MEL评分越高,缓解率越高,PFS和OS越长(P<.001)。
核心结论
- 治疗前肿瘤活检样本中PD-L1表达与缓解率、无进展生存期和总生存期相关;但PD-L1阴性肿瘤患者也可能获得持久缓解。
研究设计与样本
- Ib期KEYNOTE-001研究(临床试验信息:NCT01295827),655例晚期黑色素瘤患者接受帕博利珠单抗10 mg/kg每2周或每3周,或2 mg/kg每3周治疗。
- 每12周根据RECIST v1.1由独立中心审查评估肿瘤应答;主要结局为客观缓解率,次要结局包括无进展生存期和总生存期。
- 采用临床试验免疫组化方法(22C3抗体)评估肿瘤及肿瘤相关免疫细胞的膜性PD-L1表达,由三名对临床结局设盲的病理学家之一按独特的黑色素瘤(MEL)0至5分评分;评分≥2(≥1%细胞膜染色)视为阳性。
主要发现
- 451例可评估PD-L1表达的患者中,344例(76%)为PD-L1阳性肿瘤;PD-L1阳性和阴性患者的人口学和分期变量分布均衡。
- MEL评分越高,缓解率越高,无进展生存期越长(风险比,0.76;95%CI,0.71至0.82),总生存期越长(风险比,0.76;95%CI,0.69至0.83)(每项P<.001)。
- MEL 0、1、2、3、4、5分的客观缓解率分别为8%、12%、22%、43%、57%和53%。
关键数值与推荐
- MEL评分≥2(≥1%细胞膜染色)定义为PD-L1阳性。
- 帕博利珠单抗给药方案:10 mg/kg每2周或每3周,或2 mg/kg每3周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for response and outcome after treatment with anti-programmed death 1 (PD-1). This study explored the relationship between anti-PD-1 activity and PD-L1 expression in patients with advanced melanoma who were treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information: NCT01295827). Patients and Methods Six hundred fifty-five patients received pembrolizumab10 mg/kg once every 2 weeks or once every 3 weeks, or 2 mg/kg once every 3 weeks. Tumor response was assessed every 12 weeks per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by independent central review. Primary outcome was objective response rate. Secondary outcomes included progression-free survival (PFS) and overall survival (OS). Membranous PD-L1 expression in tumor and tumor-associated immune cells was assessed by a clinical trial immunohistochemistry assay (22C3 antibody) and scored on a unique melanoma (MEL) scale of 0 to 5 by one of three pathologists who were blinded to clinical outcome; a score ≥ 2 (membranous staining in ≥ 1% of cells) was considered positive. Results Of 451 patients with evaluable PD-L1 expression, 344 (76%) had PD-L1-positive tumors. Demographic and staging variables were equally distributed among PD-L1-positive and -negative patients. An association between higher MEL score and higher response rate and longer PFS (hazard ratio, 0.76; 95% CI, 0.71 to 0.82) and OS (hazard ratio, 0.76; 95% CI, 0.69 to 0.83) was observed ( P < .001 for each). Objective response rate was 8%, 12%, 22%, 43%, 57%, and 53% for MEL 0, 1, 2, 3, 4, and 5, respectively. Conclusion PD-L1 expression in pretreatment tumor biopsy samples was correlated with response rate, PFS, and OS; however, patients with PD-L1-negative tumors may also achieve durable responses.
引用
- Daud AI, Wolchok JD, Robert C, et al. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol. 2016. PMID: 27863197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。